Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $2.97 in the prior trading day, Fulcrum Therapeutics Inc (NASDAQ: FULC) closed at $2.96, down -0.34%. In other words, the price has decreased by -$0.34 from its previous closing price. On the day, 0.8 million shares were traded.
Ratios:
Our goal is to gain a better understanding of FULC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.63 and its Current Ratio is at 22.63. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on September 13, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $17 previously.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on September 12, 2024, whereas the target price for the stock was revised from $15 to $4.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 07 ’24 when Tourangeau Greg sold 236 shares for $7.76 per share. The transaction valued at 1,831 led to the insider holds 11,571 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.00 while its Price-to-Book (P/B) ratio in mrq is 0.66.
Stock Price History:
Over the past 52 weeks, FULC has reached a high of $12.40, while it has fallen to a 52-week low of $2.86. The 50-Day Moving Average of the stock is -24.78%, while the 200-Day Moving Average is calculated to be -45.17%.
Shares Statistics:
A total of 53.97M shares are outstanding, with a floating share count of 47.84M. Insiders hold about 11.37% of the company’s shares, while institutions hold 86.70% stake in the company.
